共 50 条
- [1] Janus-Kinase-Inhibitor Baricitinib bei rheumatoider ArthritisRandomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy (RA-BEAM)Janus kinase inhibitor baricitinib for rheumatoid arthritisRandomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)rheuma plus, 2018, 17 (3) : 103 - 105R. AltenS. Nitschmann
- [2] EFFICACY AND SAFETY OF BARICITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: SUMMARY RESULTS FROM THE 52-WEEK PHASE 3 RA-BEAM STUDYRHEUMATOLOGY, 2017, 56 : 26 - 27Taylor, Peter C.Krogulec, MarekDudek, AnnaDudler, JeanDrescher, EditCseuz, ReginaKausiene, RasaAndersone, DainaUnikiene, DaliaSanchez Burson, JuanBlanco Alonso, RicardoDvorak, ZdenekGhizdavescu, AndreiIrto, IldikoLarsson, EsbjornBello, NataliaBarry, JaneDurand, FrederickHolzkaemper, ThorstenOtawa, Susande Bono, StephanieKeystone, Edward C.Rubbert-Roth, AndreaCombe, BernardDe La Torre, Inmaculada
- [3] Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 333 - 340Keystone, Edward C.Taylor, Peter C.Drescher, EditSchlichting, Douglas E.Beattie, Scott D.Berclaz, Pierre-YvesLee, Chin H.Fidelus-Gort, Rosanne K.Luchi, Monica E.Rooney, Terence P.Macias, William L.Genovese, Mark C.
- [4] Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 StudyARTHRITIS & RHEUMATOLOGY, 2015, 67Taylor, Peter C.Keystone, Edward C.van der Heijde, D.Tanaka, YoshiyaIshii, TaekoEmoto, KahakuYang, LiliArora, VipinGaich, Carol L.Rooney, TerenceSchlichting, Douglas E.Macias, Williamde Bono, StephanieWeinblatt, Michael E.
- [5] Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE studyTHERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13Yang, YueXu, JianhuaXu, JianLi, XingfuHu, JiankangLi, XiangpeiZhang, XiaoHe, DongyiBao, ChundeLi, ZhijunWang, GuochunZerbini, Cristiano A. F.Spindler, Alberto J.Kannowski, Carol L.Wu, HanjunJi, FeiZhan, LujingLiu, MengruLi, Zhanguo
- [6] Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled StudyJOURNAL OF RHEUMATOLOGY, 2016, 43 (03) : 504 - 511Tanaka, YoshiyaEmoto, KahakuCai, ZhihongAoki, TakehiroSchlichting, DouglasRooney, TerenceMacias, William
- [7] Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-Week, Double-Blind, Randomized Placebo-Controlled StudyJOURNAL FUR MINERALSTOFFWECHSEL & MUSKULOSKELETTALE ERKRANKUNGEN, 2016, 23 (02): : 60 - 60Lunzer, R.
- [8] Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis and an inadequate response to background methotrexate therapy: Results of a phase 3 studySWISS MEDICAL WEEKLY, 2016, 146 : 9S - 9STaylor, P. C.Keystone, E. C.van der Heijde, D.Tanaka, Y.Ishii, T.Emoto, K.Yang, L.Arora, VGaich, C.Rooney, T.Schlichting, D.Macias, W. L.de Bono, S.Weinblatt, M. E.
- [9] EFFICACY AND SAFETY OF HLX01 COMBINED WITH METHOTREXATE IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD INADEQUATE RESPONSES TO METHOTREXATE: RESULTS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDYANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1122 - 1123Zeng, X.Liu, J.Liu, X.Wu, L.Liu, Y.Liao, X.Liu, H.Hu, J.Lu, X.Chen, L.Xu, J.Jiang, Z.Lu, F.Wu, H.Sun, L.Wang, M.Yu, X.Wang, Q.
- [10] BARICITINIB, METHOTREXATE, OR BARICITINIB PLUS METHOTREXATE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD RECEIVED LIMITED OR NO TREATMENT WITH DMARDS: EFFICACY AND SAFETY RESULTS FROM THE 52-WEEK PHASE 3 RA-BEGIN STUDYRHEUMATOLOGY, 2017, 56 : 134 - 135Durez, PatrickWalker, DavidGeusens, PietVan den Bosch, FilipShaikh, SaeedRoccatello, DarioTahir, HasanZamani, OmidStoykov, IvayloOtawa, SusanRogai, VeronicaLarsson, EsbjornHolzkaemper, ThorstenArthanari, SubhashiniPum, GeorgLeage, Soyi LiuGjertsson, IngerPuttini, Piercarlo SarziKekow, JoernDe La Torre, Inmaculada